Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development

Chemical Compounds

• Inducer 99%
• Cytochrome P450 91%
• Structure-Activity Relationship 73%
• Drug 44%
• Torasemide 9%
• Tienilic Acid 9%
• Suprofen 9%
• (S)-Warfarin 8%
• Dapsone 8%
• Pharmacological Metabolism 8%
• Tolbutamide 7%
• Androstane 7%
• Losartan 7%
• Pregnane 7%
• Celecoxib 7%
• Phenytoin 7%
• Retinoid 7%
• Melatonin 6%
• Glucocorticoid 6%
• Dexamethasone 6%
• Phenobarbital 6%
• Diclofenac 6%
• Arachidonic Acid 5%
• Site-Directed Mutagenesis 5%
• Steroid 4%
• Ligand 4%
• Occurrence in Nature 4%
• Toxic 4%
• Metabolite 3%
• Crystal Structure 2%
• Acid 1%

Medicine & Life Sciences

• Structure-Activity Relationship 100%
• Cytochrome P-450 Enzyme System 83%
• Drug Development 80%
• Ligands 17%
• Dexlansoprazole 9%
• Suprofen 9%
• Catalytic Domain 9%
• Ticrynafen 9%
• Torsemide 8%
• Pharmaceutical Preparations 8%
• constitutive androstane receptor 7%
• Silybin 7%
• Pregnane X Receptor 7%
• Tolbutamide 6%
• Dapsone 6%
• Celecoxib 6%
• Losartan 6%
• Diclofenac 5%
• Glyburide 5%
• Phenytoin 5%
• Retinoids 5%
• Substrate Specificity 5%
• Glucocorticoid Receptors 5%
• Phenobarbital 5%
• Enzymes 5%
• Melatonin 5%
• Site-Directed Mutagenesis 5%
• Rifampin 5%
• Warfarin 5%
• Drug Discovery 5%
• Arachidonic Acid 5%
• Drug Interactions 4%
• Dexamethasone 4%
• Acids 3%
• Steroids 3%
• Poisons 3%
• Liver 2%
• Therapeutics 0%